The role of inhaled steroids in the treatment of COPD
The aim of COPD treatment is to reduce symptoms and prevent exacerbations. The pharmacological treatment is based on bronchodilator treatment which reduces symptoms and prevents exacerbations. If patients have exacerbations despite bronchodilator treatment it is important to consider adding inhaled corticosteroids (ICS). Concomitant asthma is always an indication for ICS treatment. Studies have shown that measurement of blood eosinophil count predicts the effect of adding ICS to bronchodilators. Higher b-eos (≥ 0,3 × 109/l) strengthens the indication for ICS. A large number of COPD patients in Sweden are treated with both bronchodilators and ICS without a history of exacerbations. It is important to assess that the indication is correct at follow up of these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:117 |
|---|---|
| Enthalten in: |
Lakartidningen - 117(2020) vom: 21. Okt. |
| Sprache: |
Schwedisch |
|---|
| Weiterer Titel: |
Tillägg av inhalationssteroider vid KOL kan förebygga försämring |
|---|
| Beteiligte Personen: |
Ställberg, Björn [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.11.2020 Date Revised 23.11.2020 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM316763055 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316763055 | ||
| 003 | DE-627 | ||
| 005 | 20231225161801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||swe c | ||
| 028 | 5 | 2 | |a pubmed24n1055.xml |
| 035 | |a (DE-627)NLM316763055 | ||
| 035 | |a (NLM)33107583 | ||
| 035 | |a (PII)20051 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a swe | ||
| 100 | 1 | |a Ställberg, Björn |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of inhaled steroids in the treatment of COPD |
| 246 | 3 | 3 | |a Tillägg av inhalationssteroider vid KOL kan förebygga försämring |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2020 | ||
| 500 | |a Date Revised 23.11.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of COPD treatment is to reduce symptoms and prevent exacerbations. The pharmacological treatment is based on bronchodilator treatment which reduces symptoms and prevents exacerbations. If patients have exacerbations despite bronchodilator treatment it is important to consider adding inhaled corticosteroids (ICS). Concomitant asthma is always an indication for ICS treatment. Studies have shown that measurement of blood eosinophil count predicts the effect of adding ICS to bronchodilators. Higher b-eos (≥ 0,3 × 109/l) strengthens the indication for ICS. A large number of COPD patients in Sweden are treated with both bronchodilators and ICS without a history of exacerbations. It is important to assess that the indication is correct at follow up of these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 700 | 1 | |a Janson, Christer |e verfasserin |4 aut | |
| 700 | 1 | |a Lindén, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Lisspers, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Larsson, Kjell |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lakartidningen |d 1965 |g 117(2020) vom: 21. Okt. |w (DE-627)NLM000007544 |x 1652-7518 |7 nnns |
| 773 | 1 | 8 | |g volume:117 |g year:2020 |g day:21 |g month:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2020 |b 21 |c 10 | ||